Please login to the form below

Not currently logged in
Email:
Password:

S-A extends Genzyme deadline further

Sanofi-aventis has said it is to extend its tender offer for all outstanding shares of Genzyme to February 15

Sanofi-aventis (S-A) has said it is to extend its tender offer for all outstanding shares of US-based biotech Genzyme to February 15.

The France-based pharmaceutical company had previously launched the tender offer to acquire Genzyme for a total of $18.5bn, or $69 a share, after failing to come to a deal with Genzyme executives.

This offer expired on January 21, with 0.4 per cent of Genzyme's shares tendered.

S-A's extended offer remains $69 per share, without interest and minus any withholding taxes. Other terms and conditions remain the same.

S-A said discussions remain ongoing regarding differences in how the companies perceive the contingent value right (CVR) for multiple sclerosis drug alemtuzumab, which Genzyme plans to market as Lemtrada.

A CVR is a right offered to shareholders of an acquired company that enables them to receive additional benefits after certain milestones or events occur. In this case, these milestones would be in the development and marketing of alemtuzumab.

In a statement, S-A said there was still disagreement regarding the CVR and that 'there is no guarantee that the parties will come to an agreement'.

24th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics